Anixa Biosciences Inc: Form 10-Q for the period ended Jul 31, 2022
Filed with the SEC on Sep 9, 2022 and accepted by EDGAR at Sep 9, 2022, 16:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-05-01 to 2022-07-31 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-11-01 to 2022-07-31 | $5.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-05-01 to 2022-07-31 | −$2.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-11-01 to 2022-07-31 | −$10.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2022-05-01 to 2022-07-31 | −$2.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-11-01 to 2022-07-31 | −$10.1m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2022-05-01 to 2022-07-31 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-11-01 to 2022-07-31 | −$0.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-05-01 to 2022-07-31 | 30,451 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-11-01 to 2022-07-31 | 30,244 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-11-01 to 2022-07-31 | −$4.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-07-31 | $24.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-07-31 | $32.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-07-31 | $32.6m | us-gaap:Assets |
| Current liabilities | At period end2022-07-31 | $1.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-07-31 | $1.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-07-31 | $31.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-025490. Last ingested by Listed: Nov 2, 2026, 08:56 ET. Listed shows no prices and gives no investment advice.